{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-091011","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2023-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.956835+00:00","generated_at":"2026-06-17T06:16:33.360159+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Alaunos amends license with Precigen; returns CAR/IL-12 rights, eliminates all payment obligations","bullets":["Alaunos returns exclusive rights to CAR (CD19 & BCMA) and IL-12 products to Precigen; retains TCR and Sleeping Beauty licenses.","All Alaunos development and commercialization obligations under the license are eliminated.","Alaunos no longer owes milestone payments (up to $52.5M per program) or royalties; Precigen's royalty obligations also removed.","Annual license payment reduced from $100,000 to $75,000.","License term now tied to expiration of last valid patent claim instead of later of patent life or 12 years post-first commercial sale."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-091011","json":"https://secwatch.observer/filing/0001193125-23-091011.json","markdown":"https://secwatch.observer/filing/0001193125-23-091011.md","text":"https://secwatch.observer/filing/0001193125-23-091011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523091011/0001193125-23-091011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523091011/d429387d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:16:33.360159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c234d786a5b0bb001eff53e3e0d1874f0ffe433b","claim":"Alaunos Therapeutics, Inc. amended Amended and Restated Exclusive License Agreement with Precigen, Inc. valued at $75,000 (effective 2023-04-03).","evidence_excerpt":"On April 3, 2023, Alaunos Therapeutics, Inc. (the “Company”) and Precigen, Inc. (“Precigen”) entered into the Amended and Restated Exclusive License Agreement (the “A&R Agreement”) which amended and restated in its entirety the original Exclusive License Agreement, dated October 5, 2018, as amended (the “Original Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523091011/0001193125-23-091011-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Precigen, Inc."},{"label":"Value","value":"$75,000"},{"label":"Effective","value":"2023-04-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}